North Carolina Support Group meeting

General
1
NORTH CAROLINA
AMYLOIDOSIS SUPPORT GROUPS MEETING
FEBRUARY 20, 2016
9 AM TO 2:30 PM
DUKE CANCER INSTITUTE
North Pavilion Building
2400 Pratt Street, Room 7015
Durham, NC 27710­­­­
Speakers:
Brendan M Weiss, MD, Director,UPenn Amyloidosis Program
http://www.med.upenn.edu/apps/faculty/index.php/g348/p8478251
AND
Sascha Tuchman, MD, Durham, NC
https://www.dukemedicine.org/find-doctors-physicians/sascha-tuchman-md
Complimentary breakfast and lunch will be served.
Please RSVP to me at ■■■■■■■■■■■■■■■■■■■■■ if you plan on attending.

Parking is available in the adjacent deck and there is a charge of $2 per hour or up to $6 per day. If you are unable to afford the parking fees, please let me know when you send your RSVP.
Several clinical trials are open at Duke University:
Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis

APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ALN-TTR02 in Transthyretin(TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP) ALN-TTR02-004
https://clinicaltrials.gov/ct2/show/NCT01789242?term=DUKE+AND+AMYLOIDOSIS&rank=3